Trial · NCT00402194
Treating the Endothelium to Restore Insulin Sensitivity
NCT00402194, Not applicable, Completed, Indiana University; results first posted 2013-09-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treating the Endothelium to Restore Insulin Sensitivity. Trials, record NCT00402194. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00402194
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treating the Endothelium to Restore Insulin Sensitivity
- NCT number
- NCT00402194
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 17 participants, actual
- Lead sponsor
- Indiana University
- Conditions
- Obesity, Insulin Resistance, Impaired Glucose Tolerance, Pre-diabetes
- Interventions
- Losartan
- First posted
- 2006-11-22
- Last updated
- 2013-09-24
- Results first posted
- 2013-09-24
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Leg Blood Flow Response to Insulin | 3 months | |
| Primary | Insulin-stimulated Leg Glucose Uptake | 3 months |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Leg Blood Flow Response to Insulin | 3 months | Liters/minute | MEAN | |
| PRIMARY | Insulin-stimulated Leg Glucose Uptake | 3 months | mmol/min | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Leg Blood Flow Response to Insulin | Treatment | Baseline Leg Blood Flow | 0.24 | Standard Deviation 0.05 | Liters/minute |
| Leg Blood Flow Response to Insulin | Placebo | Baseline Leg Blood Flow | 0.26 | Standard Deviation 0.05 | Liters/minute |
| Leg Blood Flow Response to Insulin | Treatment | Insulin stimulated leg blood flow | 0.353 | Standard Deviation 0.327 | Liters/minute |
| Leg Blood Flow Response to Insulin | Placebo | Insulin stimulated leg blood flow | 0.046 | Standard Deviation 0.049 | Liters/minute |
| Insulin-stimulated Leg Glucose Uptake | Treatment | 0.42 | Standard Deviation 0.08 | mmol/min | |
| Insulin-stimulated Leg Glucose Uptake | Placebo | 0.30 | Standard Deviation 0.09 | mmol/min |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment | 9 | |
| Overall Study | STARTED | Placebo | 8 | |
| Overall Study | COMPLETED | Treatment | 9 | |
| Overall Study | COMPLETED | Placebo | 8 | |
| Overall Study | NOT COMPLETED | Treatment | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Treatment | 0 | 9 |
| Total, other adverse events | Placebo | 0 | 8 |
| Total, serious adverse events | Treatment | 0 | 9 |
| Total, serious adverse events | Placebo | 0 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Treatment vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00402194
GET https://conductscience.org/api/trials/v1/NCT00402194/registered